Activation domain requirements for disruption of Epstein-Barr virus latency by ZEBRA

Journal of Virology

Volumn 71, Issue 9, 1997, Pages 6547-6554

  Ašković, Srdjan ^a   Baumann, Ray ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; EPSTEIN BARR VIRUS; GENE DELETION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; VIRUS EXPRESSION; VIRUS REPLICATION;

EID: 1842366110     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.9.6547-6554.1997     Document Type: Article

References (48)

1. Altschul, S. F., W. Gish, W. Miller, E. Myers, and D. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410. .
2. Askovic, S., and R. Baumann. Unpublished data.
3. Askovic, S., and R. Baumann. 1997. An alternative system for detecting and mapping activation domains. BioTechniqucs 22:948-951.
4. Baumann, R., E. Grogan, M. Ptashne, and G. Miller. 1993. Changing Epstein-Burr viral ZEBRA protein into a more powerful activator enhances its capacity to disrupt latency. Proc. Natl. Acad. Sci. USA 90:4436-4440.
5. Baumann, R., G. Warren, and S. Askovic. 1995. Restoration of the Epstein-Barr virus ZEBRA protein's capacity to disrupt latency by the addition of heterologous activation regions. Virology 211:64-72.
6. Cayrol, C., and E. K. Flemington. 1996. The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dcpendeni kinase inhibitors, EMBO J. 15:2748-2759.
7. Cayrol, C., and E. K. Flemington. 1995. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor βigh3 (TGF-βigh3) and TGF-βl. J. Virol. 69:4206-4212.
8. Cayrol, C., and E. K. Flemington. 1996. G0/G1 growth arrest mediated by a region encompassing the basic lcucinc zipper (bZIP) domain of the EpsteinBarr virus transactivator Zta. J. Biol. Chem. 271:31799-31802.
9. Chavrier, P., H. Gruffat, A. Chevallier-Greco, M. Buisson, and A. Sergeant. 1989. The Epstein-Barr virus early promoter DR contains a cis-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities. J. Virol. 63:607-614.
10. Chevalller-Grevn, A., E. Munet, P. Chavrier, C. Mosnier, J. Daillie, and A. Sergeant. 1986. Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required lo activate transcription from an EBV early promoter. EMBO J. 5:3243-3249.
11. Chevallier-Greco, A., H. Gruffat, E. Manet, A. Calender, and A. Sergeant. 1989. The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive and cell specific, domain B is transactivatcd by the EBV early protein R. J. Virol. 63:615-623.
12. Chi, T., and M. Curey. 1993. The ZEBRA activation domain: modular organization and mechanism of action. Mol. Cell. Biol. 13:7045-7055.
13. Countryman, J. K., and G. Miller. 1985. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogenous viral DNA. Proc. Natl. Acad. Sci. USA 82:4085-4089.
14. Cox, M. A., J. Leahy, and J. M. Hardwick. 1990. An enhancer within the divergent promoter of Epstein-Barr virus responds synergislically to the R and Z transactivators. J. Virol. 64:313-321.
15. Davis, M. G., and E. Huang. 1988. Transfer and expression of plasmids containing human cytomegalovirus immediate-early gene 1 promoter enhancer sequences in eukaryotic and prokaryotic cells. Biotechnol. Appl. Biochem. 10:6-12.
16. Fixman. E. D., G. S. Hayward, and S. D. Hayward. 1992. fww-acting requrcments for replication of Epstein-Barr virus ori-Lyt. J. Virol. 66:5030-5039.
17. Fixman, E. D., G. S. Hayward, and S. D. Hayward. 1995. Replication of Epstein-Barr virus ori Lyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays, J. Virol. 69:2998-3006.
18. Flemington, E. K., A. M. Borras, J. P. Lytle, and S. H. Speck. 1992. Characterization of the Epstein-Barr virus BZLF1 protein transnctivation domain. J. Virol. 66:922-929.
19. Giot, J., I. Mikaelian, M. Buisson, E. Mante, T. Joab, J. Nicholas, and A. Sergeant, 1991. Transcriptional interference between the EBV transcription factors EB1 and R: both DNA-binding and activation domains of EB1 are required. Nucleic Acids Res. 19:1251-1258.
20. IYt enhancer is not B-cell specific and does not respond synergistically to the EBV transcription factors R and Z. J. Virol. 64:2810-2818.
21. Gutsch, D. E., E. A. Holley-Guthrie, Q. Zhang, B. Stein, A. A. Blanar, A. S. Baldwin, and S. C. Kenney. 1994. The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with ihe p65 subunit of NF-KB. Mol. Cell. Biol. 14:1939-1948.
22. Hammerschmidt, W., and B. Sugden. 1988. Identification and characterization of oriLyt, a lytic origin of DNA replication of Epslcin-Barr virus, Cell 55:427-433.
23. Hardwick, J. M., P. M. Lieberman, and S. D. Hayward. 1988. A new EpsteinBarr virus transactivator. R. induces expression of a cytoplusmic early antigen. J. Virol. 62:2274-2284.
24. Hatfull, G., A. T. Bankier. B. G. Barrell, and P. J. Farell. 1988. Sequence analysis of RAJI Epstein-Barr virus DNA. Virology 164:334-340.
25. Hoey. T., R. O. J. Weinzieri, G. Gill, J. L. Chen, B. L. Dynlacht, and K. Tjian. 1993. Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators. Cell 72:247-260.
26. Kenney, S., J. Kamine, G. E. Holley, J. C. Lin, E. C. Mar, and J. Pagano. 19S9. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J. Virol. 63: 1729-1736.
27. Kolman, J. L., N. Taylor, L. Gradoville, J. Countryman, and G. Miller. 1996. Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras. J. Virol. 70:1493-1504.
28. Le Roux, F., A. Sergeant, and L. Corbo. 1996. Epstcin-Barr virus (EBV) EBl/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLFl gene in the EBV ge-nomc. J. Gen. Virol. 77:501-509.
29. Lieberman, P. M., J. M. Hardwick, and S. D. Hayward. 1489. Responsiveness of the Epstein-Barr virus Notl repent promoter to the Z transactivator is mediated in a cell-type-specific manner hy two independent signal regions. J. Virol. 63:3040-3050.
30. Lieberman, P. M., J. M. Hardwick, J. Sample, G. S. Hayward, and S. D. Hayward. 1990. The Zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J. Virol. 64:1143-1155.
31. Lieberman, P. M., and A. J. Berk. 1991. The Zta transactivator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes Dev. 5:2441-2454.
32. Marshal, D., and C. Sample. 1995. Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J. Virol. 69:3624-3630.
33. Miller, G. 1990. Epstein-Barr virus: biology, pathogenesis and medical aspects, p. 1921-1958. In B. N. Fields. D. M. Knipe. R. M. Chanock. M. S. Hirsch, J. L. Melnick. T. P. Monnth. and B. Roizman (ed.). Virology. Raven Press. Ltd., New York, N.Y.
34. Mitchell, P. J., and R. Tjlan. 1989. Transcriptional regulation in mammalian cells hy sequence-specific DNA binding proteins. Science 245:371-378.
35. Qian, Z., P. Brunovskis, F. Kauscher III, L. Lee, and II.-J. Rung. 1995. Transactivation activity of Meq. a Marek's disease hcrpcsvirus bZIP protein persistently expressed in latently infected transtormed T cells. J. Virol. 69: 4037-4044.
36. Rabson, M., L. Heston, and G. Miller. 1983. Identification of a rare Epstein-Burr virus variant that enhances early antigen expression in Raji cells. Proc. Natl. Acad. Sci. USA 80:2762-2766.
37. Rooney, C. M., D. T. Rowe, T. Ragot, and P. J. Farrcll. 1989. The spliced BZLF1 gene of Epstcin-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63:3109-3116.
38. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor Laboratory Press. Cold Spring Harbor. N.Y.
39. Sarlsky, R., Z. Gao, P. M. Lieberman, E. D. Fixman. G. S. Haywurd, and D. Hayward. 1996. A replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator. J. Virol. 70:8340-8347.
40. Schepers, A., D. Pich, J. Mankcrtz, and W. Hammerschmidt. 1993. cis-acting elements in the lytic origin of DNA replication of Epstein-Barr virus. J. Virol. 67:4237-4245.
41. Schepers, A., D. Pich, and W. Hammerschmidt. 1993. A transcription Factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr vims. EMBO J. 12:3921-3929.
42. Schepers, A., D. Pich, and W. Hammerschmidt. 1996. Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1. Virology 220:367-376.
43. Sista, N. D., J. S. Pagano, W. Liao, and S. Kenncy. 1993. Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc. Natl. Acad. Sci. USA 90:3894-3898.
44. Taylor, N., J. Countryman, C. Rooney, D. Katz, and G. Miller. 1989. Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses. J. Virol. 63:1721-1728.
45. Yates, L., N. Warren, D. Reismann, and B. Sugden. 1984. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc. Natl. Acad. Sci. USA 81:3806-3810.
46. Znlani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF protein through a cellspecific mechanism. Proc. Natl, Acad. Sci. USA 93:9194-9199.
47. Zhang, Q., Y. Hong, U. Dorsky, E. Holley-Guthrie, S. Zalani, N. A. Elshiekh, A. Kiehl, T. Le, and S. Kenney, 1496. Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: effects on EBV transcription and lytic replication. J. Virol. 70:5131-5142.
48. Zhang, Q., D. Gutsch, and S. Kenney. 1994. Functional and physical interactions between p53 and BZLF1: implications for Epstcin-Barr latency. Mol. Cell. Biol. 14:1929-1938.